Physiologic disposition and metabolic fate of indomethacin analogs. II. 1-(p-chlorobenzoyl)-5-dimethylamino-2-methylindole-3-acetic acid.
D000284:Administration, Oral; D000818:Animals; D001565:Benzoates / Q000378:metabolism / Q000502:physiology; D001646:Bile / Q000032:analysis; D002247:Carbon Isotopes; D004285:Dogs; D005243:Feces / Q000032:analysis; D005965:Glucuronates / Q000378:metabolism; D006168:Guinea Pigs; D006626:Hippurates / Q000378:metabolism; D006801:Humans; D007210:Indoleacetic Acids / Q000378:metabolism* / Q000502:physiology*; D007213:Indomethacin / Q000097:blood / Q000378:metabolism / Q000652:urine; D007408:Intestinal Absorption; D008297:Male; D008744:Methylamines / Q000378:metabolism / Q000502:physiology; D051379:Mice; D011817:Rabbits; D051381:Rats; D013045:Species Specificity; D013997:Time Factors
D001565:Benzoates; D002247:Carbon Isotopes; D005965:Glucuronates; D006626:Hippurates; D007210:Indoleacetic Acids; D008744:Methylamines; D007213:Indomethacin